Navigation Links
AMDL's Goodnak(R) Anti-Aging Skin Care Line Soon Available in Capsule & Lotion Form
Date:6/24/2008

Easy-to-use formulations help broaden market penetration in China

TUSTIN, Calif., June 24 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), (http://www.amdl.com), a leader in specialty pharmaceuticals, announced today its subsidiary Jade Pharmaceutical, Inc. (JPI) anticipates releasing during the 3rd quarter of 2008 two new formulations of its popular Goodnak(R) anti-aging skin care product line. In addition to its high quality injectable formulation, JPI anticipates offering Goodnak in capsules and an easy-to-apply lotion.

Based on general market information, the proposed pricing for these new formulations will be approximately US$40.00 per unit, with 60% gross profit margins. JPI plans to sell both products through existing distribution channels within the Henan, Sichuan, Guizhou, Shanxi, Xinjiang, Gansu, Hunnan, Zhejiang, Fujian, Liaoning and Heilongjiang Provinces of China. Together these regions have a combined population of more than 376 million people. In addition to China, AMDL believes both products will be good candidates for export to the North American and European markets.

According to Gary Dreher, CEO of AMDL, "With the popularity of the Goodnak brand in China, combined with JPI's ability to sell through pre-approved distribution channels, we anticipate sales to exceed well beyond our initial annual sales forecast for Goodnak of $24 million. This is extremely positive news for the market, Company and our shareholders."

Additional information on AMDL, Goodnak and the Company's other pharmaceutical products is available at http://www.amdl.com.

About AMDL:

AMDL, Inc. is a global specialty pharmaceutical Company. The Company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The Company employs approximately 320 people in the U.S. and China.

About Jade Pharmaceutical:

JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: Kristine Szarkowitz

206.310.5323

kszarkowitz@amdl.com


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. William S. Gruss, M.D., Says That Medical Research Shows You Can Reduce Your Risk of Cancer By Up To 77% and Reverse the Effects of Aging in A CARDIOLOGISTS GUIDE TO ... ANTI-AGING, ANTIOXIDANTS & RESVERATROL
2. Parisian Peel(R) Introduces Anti-Aging Suffusion System
3. Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally
4. NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures
5. Breakthrough Acai Berry Anti-Aging Facial Applies Benefits of Natures Super-Food to the Skin
6. New ingredients in drug-like anti-aging products improve skin
7. Chinas Anti-Aging Revolution
8. AUDIO from Medialink and Allergan: Women Not Sure Who to Trust on Anti-Aging Skin Care
9. TRIA Personal Laser Hair Removal System Now Available at Aesthetic Physician Offices
10. WuXi PharmaTech 2007 Annual Report Available Online
11. New Resource Available for Families Seeking Quality Care for Aging Parents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Groth Family ... Pasco and Richland, is initiating a charity drive to support the family of ... recent automobile collision. , On October 29th of this year, Cindy Hendrickson ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... celebrated its 10th anniversary with the grand opening of the Sober College Robert ... event spanned two days, December 2-3, and was attended by an overwhelming amount ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio , founder ... national #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer ... Gives Back initiative, and we’re very pleased with the participation in every ...
(Date:12/8/2016)... ... 2016 , ... With the increasing demand for dental implants, the National Association ... to inform dentists and patients about the safety issues related to dental restorations. According ... the U.S. is projected to reach $6.4 billion in 2018 with more than 30 ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... grow in 2017-2023. Various reasons for growth of the ... higher incidences of chronic diseases, high recovery cost of ... services. Medical lifting sling refers to an assistive ... mobility. These slings connect to the lift and hold ...
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... Dec. 8, 2016   TriNetX , the ... Children,s Hospital signed a membership agreement to ... development of new cures. The TriNetX ... 57 million patients globally, biopharmaceutical companies and contract ... improve protocol design, site selection, patient recruitment, and ...
Breaking Medicine Technology: